CisplatinDeoxycytidineAntimetabolites, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsPancreatic NeoplasmsAntineoplastic AgentsDrug Administration ScheduleDeoxycytidine KinaseLung NeoplasmsDrug Resistance, NeoplasmTreatment OutcomeVinblastinePaclitaxelInfusions, IntravenousCarcinoma, Non-Small-Cell LungPlatinumCell Line, TumorBiliary Tract NeoplasmsAdenocarcinomaFluorouracilTaxoidsCombined Modality TherapyCarboplatinDrug SynergismDose-Response Relationship, DrugMaximum Tolerated DoseDisease-Free SurvivalNeutropeniaSurvival RateEquilibrative Nucleoside Transporter 1Ovarian NeoplasmsApoptosisLeukopeniaDrug Screening Assays, AntitumorXenograft Model Antitumor AssaysUrologic NeoplasmsEtoposideNeoplasm StagingRadiation-Sensitizing AgentsNauseaVomitingMice, NudeCarcinoma, Transitional CellThrombocytopeniaOxonic AcidCamptothecinCarcinoma, Pancreatic DuctalDoxorubicinIfosfamideNeoplasm MetastasisGuanineDNA AdductsNeoplasmsTegafurLead RadioisotopesTumor Cells, CulturedUrinary Bladder NeoplasmsRibonucleoside Diphosphate ReductaseCarcinoma, Squamous CellHead and Neck NeoplasmsCell SurvivalOrganoplatinum CompoundsAntineoplastic Agents, PhytogenicCA-19-9 AntigenGlutamatesDisease ProgressionSalvage TherapyGallbladder NeoplasmsNeoplasm Recurrence, LocalCarcinomaCell ProliferationChemotherapy, AdjuvantPleural NeoplasmsMesotheliomaEpirubicinMitomycinKaplan-Meier EstimateInhibitory Concentration 50Hematologic DiseasesRibonucleotide ReductasesNeoadjuvant TherapyQuinazolinesTime FactorsDNA DamageTesticular NeoplasmsSurvival AnalysisFloxuridinePrognosisVindesineGene Expression Regulation, NeoplasticPeritoneal NeoplasmsCarcinoma, Small CellAdministration, IntravesicalArea Under CurveNeoplasms, Unknown PrimaryCell CycleRemission InductionPlatinum CompoundsDNA RepairUrothelium